Inflammatory Bowel Disease: A Focus On Biologics
| Overview / Abstract: |
The 2 main types of inflammatory bowel disease (IBD), Crohn’s disease (CD) and ulcerative colitis (UC), affect approximately 1.17 million people in the United States. The estimated prevalence of CD in North America is 26-199 cases per 100,000 people; for UC, it is 37-246 cases per 100,000 people. During the past 25 years, the rates of newly diagnosed UC and CD cases have increased. Reasons for the increase may include wider exposure to environmental risk factors, greater awareness of IBD, and improved diagnostic methods. A variety of treatments are available to manage IBD. This issue focuses on the new biologic agents and their place in the treatment of CD and UC. Community practitioners are an important source of patient education regarding the biologic agents used to treat IBD. Patients need counseling about self-injection techniques for subcutaneously administered products, adverse effects, and precautions. Community practitioners also have a role in monitoring for the effectiveness and toxicity of biologic agents. |
|
Expiration |
Nov 23, 2019 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE |
|
Format |
Monograph, Online |
|
Cost |
6.95 |
|
Credits / Hours |
1.5 |
|
Accreditation |
ACPE |
|
Presenters / Authors / Faculty |
Sheila Wilhelm, Pharm.D., FCCP, BCPS |
|
Keywords / Search Terms |
Continuing Education Network Inc. inflammatory bowel disease, Crohn’s disease, ulcerative colitis, IBD, biologic agents |
|